AGIO - Agios Pharm logo

Agios Pharm

AGIO

Agios Pharmaceuticals discovers and develops medicines targeting cellular metabolism, focusing on hemolytic anemias, sickle cell disease, thalassemia, and rare diseases. Its key products include PYRUKYND and tebapivat, aimed at addressing unmet medical needs.

โš•๏ธ Healthcare NASDAQ Listed 2013 $ USD
$1,000 invested 10 years ago โ†’$753today

Score Overview

1 Year
Score
Net Growth0.36%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth82.01%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-125.63%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth-107.23%
Net Trend40%
Net Income Consistency
Rev Growth40.70%
Rev Trend88%
Revenue Consistency
All Time
Score
Net Growth-8x
Net Trend31%
Net Income Consistency
Rev Growth284.91%
Rev Trend82%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Agios Pharm has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AGIO does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 37.00โ€”
1 Year2025-10-23
$ 42.09-12.09%
5 Years2021-10-22
$ 48.55-23.79%
10 Years2016-10-21
$ 49.12-24.67%
All Time2013-07-24
$ 31.2818.29%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 98M-$ 411M$ 617M
2025$ 54M-$ 412M$ 854M
2024$ 36M$ 673M$ 893M
2023$ 26M-$ 352M$ 776M
2022$ 14M-$ 231M$ 783M
2021$ 1.60B$ 1.02B
2020$ 203M-$ 327M$ 572M
2019$ 117M-$ 411M$ 564M
2018$ 94M-$ 346M$ 805M
2017$ 43M-$ 314M$ 567M
2016$ 69M-$ 198M$ 573M
2015$ 59M-$ 117M$ 375M
2014$ 65M-$ 53M$ 342M
IPO2013$ 25M-$ 39M$ 166M
AGIO - Agios Pharm logo

Agios Pharm fundamental performance

Between 2015 and 2025, revenue declined from $ 59M to $ 54M and net income went from -$ 117M to -$ 412M. Revenue increased in 9 of those 10 years; net income in 4.

Membership

Explore AGIO with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies